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ABSTRACT
BACKGROUND: Glucagon-like peptide-l (Gl P-I) receptor agonisrs are a new
class of hypog lycemic drugs, including exenatide, liraglut ide, albiglut ide, lixisenatide,
and raspoglutide. Insul in gla rgine is a standard agent used to supplement basal insulin
in type 2 d iabetes mell itu s (T2 0M).
OBJECTIVE: The aim of th is stu dy was to review th e efficacy and safety profi les
of GLP-l receptor agonises versus insulin glargine in type 2 diabeti c patie nts who have
not achieved treatment goals with oral hypog lycem ic agents .
METHODS: The Cochrane l ibrary, MEOLINE, EMBASE, Science Citat ion Index
Expanded , and th e database of ongoi ng tr ials were searched from incep tio n th rough
April 2010 . Add itional dam were sought from relevant Web sites, the American Diabetes
Associat ion, reference lists of included trials and related (systema tic) reviews, and in-
dus try. Randomized controlled tria ls (RCTs) were selected if they were ~3 months in
duration, compa red GLP-l receptor agonists with insu lin glargine in patients wit h
T20M, and included z l of the following outcomes: mortality, complicati ons ofT20 M,
glycemic control, weig ht, lipids, blood pressure, adver se effects, and health-related
qua lity of life. Quasirandomized cont rolled trials were excluded. The quality of the
eligible studies was assessed on the basis of the following aspects: randomization pro-
cedure, allocation concealment , blinding , incomplete outcome data (intent-to-treat
[ITT} analysis), selective outcome reporting , and pu blication bias.
RESULTS: A total of 410 citatio ns were ret rieved ; 5 mu lti center RCTs th at met
the inclusion criteria were identified . T hey were all open- label designs wi th an insulin
glargine arm , predefined outcomes reported, and ITT analysis. One tr ial had an unclear
randomizatio n procedure and allocation concealment. Publication bias was not able to
be determ ined . No data were found with regard to mortality or diabetes-associated
complications, and few data were found on quality of life. The resul ts of th e meta-
analysis suggest th at insulin g largine was significantly better in reducing the fast ing
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blood glucose (mean difference {MD} {95% Cl], 1.31 {1.04 to 1.58}; P < 0.001), but
exhibits greater incidence of nocturnal hypoglycemia (risk ratio {RR} {95% Cl], 0.40
{0.23 to 0.7l}; P = 0.002) and influenza (RR {95% Cl], 0.56 {0.32 to 0.98}; P = 0.04).
GLP-1 receptor agonists are more conducive to reducing weight (MD {95% Cl],
-3.96 {-5.14 to -2.77}; P < 0.001), postprandial blood glucose (after breakfast, P <
0.001; after dinner, P < 0.001), and LDL-C (MD {95% en, -0.18 {-0.28 to -0.08};
P < 0.001), but have significantly more gastrointestinal adverse effects (eg, nausea/
vomiting, P < 0.001). There were no significant differences between GLP-1 receptor
agonists and insulin glargine in reducing glycosylared hemoglobin (HbA1c) levels
(MD {95% Cn, -0.03 {-0.13 to 0.08}) and the overall incidence of hypoglycemia (RR
{95% en, 0.69 {0.42 to 1.14}).
CONCLUSIONS: Compared with insulin glargine, GLP-1 receptor agonists did
not have a significant difference in regard to reducing HbA1c levels and they were sig-
nificantly associated with decreased weight but increased gastrointestinal adverse events.
It remains unclear whether GLP-1 receptor agonists influence mortality or diabetes-
associated complications in patients with T2DM. More trials with longer follow-up
are needed to determine the exact long-term efficacy and safety profiles of this new
class of hypoglycemic drugs. (Curr Tber Res Clin Exp. 2010;71:211-238) © 2010
Excerpta Medica Inc.
KEY WORDS: type 2 diabetes, diabetes mellirus, GLP-1, glucagon-like peptide-I,
insulin glargine, insulin detemir, meta-analysis.
INTRODUCTION
Diabetes is a major public health problem. In 2000, there were 171 million patients
with diabetes mellitus worldwide, and the number is predicted to increase to 366 mil-
lion by 2030. 1 The World Health Organization (WHO) estimated that almost 3 million
deaths per year worldwide are the resulr of diabetes. Type 2 diabetes mellitus (T2DM)
represents -90% of all cases of diabetes; the main pathogenesis of T2DM includes
insulin secretory dysfunction, insulin resistance, and excess glucagon secretion.? Phar-
macologic treatments are mainly directed against 2 aspects: insulin secretory dysfunction
and insulin resistance. Pharmacologic treatments include sulfonylurea and meglitinides
to increase insulin secretion, a variety of insulins to supplement the low level of
endogenous insulin, and thiazolidinediones and metformin to decrease insulin resis-
rance.i These drugs hardly improve the gradual decline in islet ~-cell function4,s and
reduce the secretion of glucagon. Moreover, adverse events (AEs) such as weight gain
and hypoglycemia have been found to increase when the dose and frequency of these
drugs are increased.v In recent years, long-acting insulin analogues and glucagon-like
peptide-1 (GLP-1) receptor agonists offer new possibilities for the treatment of hyper-
glycemia in people with T2DM.7,8
Insulin glargine was the first long-acting insulin analogue produced by recombi-
nant DNA technology, approved for treatment of both type 1 diabetes and T2DM by the
US Food and Drug Administration (FDA) in April 2000 and by the European Agency for
the Evaluation of Medicinal Products in June 2000. 8Becauseof its long duration of action
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without a pronounced peak, it is primarily used to supplement basal insulin. It has been
used in many countries, such as the United States and China, because of its low risk and
high compliance rates." Insulin detemir is another type of long-acting insulin analogue,
approved by the FDA in 2005.9 It is also used to supplement basal insulin.
GLP-1 is associated with enhanced glucose-induced insulin secretion, reduced weight,
and inhibited glucagon secretion, gastrointestinal motility, appetite, and food intake
when it is released into the blood circulation from the gut. 10-13 Preclinical data sug-
gest that GLP-1 also has some important characteristics including enhancement of
insulin biosynthesis and insulin-gene transcription, improvement of ~-cell function
and mass, and reduction of apoptosis of ~-cells.14 GLP-1 receptor agonises are more
resistant to degradation and have a longer half-life and similar pharmacokinetic prop-
erties? compared with native GLP-1; therefore, GLP-1 receptor agonists can better
control blood glucose. Exenatide and liraglutide were the 2 earliest developed GLP-1
receptor agonists. Exenatide is the synthetic form of naturally occurring exendin-4, a
potent agonist of mammalian GLP-1 receptors, and the amino acid sequence overlap
with GLP-1 is 53%.15,16 Liraglutide is a recombinant, acylated analogue of human
GLP-1 and has 97% sequence homology to native GLP-l.17 Exenatide was approved
by the FDA in 2005 as an adjunctive treatment for T2DM in patients unable to
achieve adequate glycemic conrrol.l'' Liraglutide!" was approved by the European
Medicines Agency for use in Europe in 2009 and the FDA approved liraglutide as an
adjunct to diet and exercise to improve glycemic control in adults with T2DM in
2010. Several other GLP-1 receptor agonists are albiglutide.e" lixisenaride.-" and raspo-
glutide22; these 3 drugs are now in Phase II or III clinical trials.
The aim of this review was to assess the efficacy and safety profiles of GLP-1 recep-
tor agonists versus insulin glargine in patients with T2DM who have not achieved
treatment goals with oral hypoglycemic agents.
MATERIALS AND METHODS
STUDY SELECTION
Randomized controlled trials (RCTs) of GLP-1 receptor agonist (exenatide, lira-
glutide, albiglutide, lixisenaride, or taspogluride) injection versus long-acting insulin
analogue (insulin glargine or insulin derernir) injection in combination with an oral
antidiabetic drug were included for this review. Parallel and crossover designs were
eligible; there were no restrictions on publication status or language. Patients were
required to be aged 2'18 years with T2DM diagnosed using WHO 199823or American
Diabetes Association (ADA) 200924 diagnostic criteria. Duration of treatment was to
be > 12 weeks of basal treatment with stable dosesof oral antidiabetic drug. Quasirandom-
ized trials were excluded.
Primary end point outcomes included: (1) mortality---diabetes-related mortality
(eg, death from myocardial infarction, stroke, peripheral vascular disease, renal dis-
ease, hyper- or hypoglycemia, or sudden death), total mortality; (2) diabetes-related
AEs-angina pectoris, neuropathy, retinopathy, nephropathy, erectile dysfunction,
and hyperosmolar nonketoric coma; and (3) health-related quality oflife (using a vali-
dated instrument)-patient-reported health outcomes.
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Secondary outcomes included: (1) glycemic control (change in glycosylated hemo-
globin {HbA1c} levels from baseline to end point), propottion of subjects achieving
HbA1c ~7%, and fasting and postprandial blood glucose levels; (2) plasma lipid levels
(triglycerides {TG}, total cholesterol {TC}, HDL-C, and LDL-C); (3) fasting and post-
prandial insulin and C-peptide levels; (4) weight (or body mass index {BMI});
(5) blood pressure (BP) (systolic BP {SBP}/diastolic BP {DBP}); (6) waist and hip
circumference, waist/hip ratio; (7) mild or moderate hypoglycemia; (8) AEs (eg,
nausea, vomiting, diarrhea, dyspepsia, constipation, upper abdominal pain, headache,
dizziness, nasopharyngitis, influenza, cough, back pain, arthralgia); and (9) costs.
LITERATURE SEARCH
The Cochrane Library (Issue 3, 2010), MEDLINE (january 1965-April 2010),
EMBASE (january 1966-April 2010), Science Citation Index Expanded 0900-April
2010), as well as an online database of ongoing trials, Current Controlled Trials, were
searched. The following search terms were used: type 2 diabetes, non insulin dependent diabetes
mellitus, exenatide, liraglutide, GLP-l, albiglutide, glucagon-like peptide 1, taspoglutide,
lixisenatide, insulinglargine, and insulindetemir. The following additional sources were
explored for additional studies: reference lists of the included trials and related (sys-
tematic) reviews or meta-analyses; the FDA and International Diabetes Federation (IDF)
Web site; and 2 pharmaceutical companies (Eli Lilly and Company, Novo Nordisk).
We also searched posters and abstracts presented at the ADA annual meetings from
2004 through 2009.
DATA EXTRACTION AND QUALITY EVALUATION
Two researchers (W.-X.I. and J.-EG.) independently cross-checked the search
results including titles, abstracts, and full texts according ro the inclusion and ex-
clusion criteria. During selection of the included trials, in the case of disagreements,
a third researcher G.-H.T.) would decide whether the trial should be included. The
main data were extracted into 2 forms and 1 table: baseline characteristics form of
the study (eg, authors, year, sponsors, design type, sample size; age, gender, BMI
intervention, duration of treatment); quality evaluation form including the follow-
ing aspects: randomization procedure, allocation concealment, method of blinding,
handling losses to follow-up (intent-to-treat {ITT} analysis), and selective outcome
reporting. Every aspect of the quality evaluation form is divided according to the
method described in the Cochrane Collaboration handbook (version 5.0.2)25 into
3 classes (yes {low risk of bias}, unclear {uncertain risk of bias}, and no {high risk of
biasj); and outcome indicators table including primary end point outcomes and
secondary outcomes.
STATISTICAL ANALYSIS
RevMan 5.0 statistical software provided by the Cochrane Collaboration was used
for statistical analysis. Measurement data were reported as mean difference (MD) and
count data were reported as relative risk (RR) for statistical analysis; both were ex-
pressed as 95% CIs. If there were different drugs, a subanalysis was used; if there were
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different design types, a sensitivity analysis was used. The X2 test was used to deter-
mine statistical heterogeneity; P < 0.1 and ]2 > 50% indicated that there was statisti-
cal heterogeneity. To handle heterogeneity, the source was determined and, if possible,
the random-effects model was used. If there was no statistical heterogeneity, the fixed-
effects model was used for data analysis. P < 0.05 was considered statistically signifi-
cant. The funnel plot of primary end point indicators or important secondary out-
comes was used as an assessment of publication bias.
RESULTS
LITERATURE SEARCH RESULTS
The systematic database search resulred in 410 relevant articles; 397 citations were
excluded after reading titles and abstracts. After reading the remaining 13 full-text
articles, 5 RCTs were included in the meta-analysis (1452 patients) (Figure 1)26-30;
the other 8 articles were found to be secondary analyses of an included RCT.26 No
additional studies were retrieved from the references listed in relevant reviews, in-
cluded articles, FDA and IDF Web sites, pharmaceutical companies, or the ADA. We
found 16 RCTs that met the inclusion criteria that are registered in the Current Con-
trolled Trials database. At the time of publication,S registered studies had been com-
pleted, which were included in the meta-analysis. The results of 11 ongoing trials were
not obtained.
BASELJNE CHARACTERISTICS OF THE INCLUDED TRIALS
The GLP-l receptor agonists experimental data found were only for exenatide and
liragluride. For long-acting insulin analogues, no articles were found on insulin dete-
mir. Four trials 26-28,30 compared exenatide and insulin glargine, and 1 trial 29 com-
pared liraglutide and insulin glargine. Four trials were of a parallel design26,2S-30 and
the other was a crossover design." The GLP-l receptor agonists-rrearment groups and
insulin glargine-treatment groups in the included trials were not significantly differ-
ent in regard to baseline data. The baseline BMI of subjects was 30.3 to 34.6 kg/rn?
(within the obesity range) in all of the included trials. The basic characteristics of
included studies are shown in Table I.
QUALITY of THE INCLUDED TRIALS
Table II shows the merhodologic quality assessment of the 5 included studies.
Random sequence generation was adequate (low risk of bias) in 4 of the trials 26-29;
1 trial '? reported that it was randomized, but did not elaborate on the specific
method used. Allocation concealment of 1 trial was unclear-"; it was adequate for
the other 4 trials. 26-29 ITT analysis was confirmed in all 5 trials. 26-30 The study
protocol was available and all of the studies' predefined outcomes were reported
in all of the included trials. Blinding was open-label in all 5 trials. Publication
bias was assessed USlOg the funnel plot of the change in HbAl c levels. As shown in
Figure 2, the funnel plot was symmetric (meaning no bias was found), but from a
relatively small number (5) of studies; therefore, publication bias was not able to
be determined.
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Citations retrieved from electronic search
(N = 410)
EMBASE (311)
MEDLINE (52)
Science Citation Index Expanded (35)
The Cochrane Library (12)
Citations excluded after reading titles and abstract (n = 397)
Incompatible with the research theme (277)
---.- Duplicate publications (64)
Reviews or editorials (55)
Retrospective study (1)
Potentially appropriate studies to be included in this meta-analysis
(n = 13)
8 Articles were secondary analyses of
1 qualified RCT
Cost-effectiveness (n =4)
The UK setting
The German setting
The Swiss setting
In the United Kingdom
Analysis of the other indicators (n = 4)
Patient-reported outcomes
Postprandial glucose excursion
Glycemic variability
Weight change
Eligible RCTs for meta-analysis
(n = 5)
Figure 1. Flow chart of study identification and selection procedure. ReT = randomized
controlled trial.
META-ANALYSIS RESULTS
Data were unavailable for mortality and diabetes-related complications. One arti-
cle31 assessed patient-reported health outcomes of the trial by Heine et a1. 26 In this
trial, patients completed 5 health outcomes instruments: Diabetes Symptom Checklist-
revised (DSC-R); Diabetes Treatment Flexibility Scale (TFS); Diabetes Treatment
Satisfaction Questionnaire (DTSQ); EuroQol EQ-5D; and the Vitality Subscale of the
SF-36 (Medical Outcomes Study 36-Item Short Form Health Survey). It reported that
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Figure 2. Funnel plot of the change in glycosylated hemoglobin levels in the 5 studies
assessed in the meta-analysis.26-30
both exenatide and insulin glargine had statistically significant baseline-to-end point
improvement in the DSC-R total score (P < 0.001 for both treatment groups), the
DTSQ Satisfaction Score (P < 0.001 for both treatment groups), and the SF-36 Vitality
Subscale Score (P = 0.005 for exenatide and P < 0.04 for insulin glargine). Group
differences were examined with general linear models controlling for country and
baseline scores. There were no significant differences between the 2 groups in the
DSC-R overall score, EQ-5D index score, TFS score, DTSQ Score, and SF-36 Vitality
Subscale Score. This secondary analysis found that, although the exenatide-treated
patients had a greater number of injections and gastrointestinal AEs, the weight-
reduction benefits associated with the drug offset its disadvantages. Meta-analysis of
the secondary indicators follows.
GLYCEMIC CONTROL
Change in Glycosylated Hemoglobin Levels
There was no significant difference between GLP-1 receptor agonists and insulin
glargine (n = 1521; MD [95% CI}, -0.03 [-0.13 to O.OS}) in regard to the reduction
of HbA1c levels from baseline to end point (Figure 3). Heterogeneity test results in-
dicated P = 0.42 and [2 = 0% using the fixed-effects model for data consolidation.
The study by Barnett et al27 (crossover design) was subjected to a sensitivity analysis
and the results were stable (n =1266; MD [95% CI}, -0.03 [-0.15 to O.OS}).
Proportion ofSubjects Achieving Glycosylated Hemoglobin 5.7%
No significant difference was found between GLP-1 receptor agonises and insulin
glargine for proportion of subjects achieving HbA1c 5.7% (n = 1563; RR [95% CI},
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1.11 [O.91-1.35}) (Figure 4). The heterogeneity test indicated P < 0.001 and [2 =
82%; therefore, the random-effects model was used for data consolidation. The results
remained unchanged after the removal of the crossover trial 27 (n = 1300; RR [95 %
en, 1.17 [O.90-1.51}).
Change in Fasting Blood Glucose Levels
There was a significant reduction (n == 1085; MD [95% Cl], 1.31 [1.04-1.58}; P <
0.001) in fasting blood glucose (FBG) levels in insulin glargine-treated patients compared
with exenatide-treated patients (Figure 5). The included 4 trials26-28,30 had no heteroge-
neity (P = 0.94, [2 = 0%). This remained significant after sensitivity analysiswithout the
crossover trial (n == 822; MD [95% cu 1.34 [1.04-1.65}; P < 0.001). The SD of FBG
was not obtained; therefore, the results of liraglutide versus insulin glargine were only
described.i? Final reductions in FBG from baseline in the liraglutide and insulin glargine
groups were 1.55 and 1.79 mmol/l, respectively.
Percentage of Patients Achieving Fasting Blood Glucose <5.6 mmollL
There were significant increases in the insulin glargine arm compared with the
exenatide arm (n == 1032; RR [95 % Cn, 0.35 [0.25-0.49}; P < 0.001) for the per-
centage of patients achieving FBG < 5.6 mmollL in 3 trials (Figure 6).26,27,30 The
heterogeneity test indicated that P = 0.66 and [ 2 = 0%. This significance remained
after removal of the crossover trial (n = 769; RR [95 % Cl], 0.37 [O.26-0.52}; P <
0.001). The other 2 trials had no data on GLP-1 receptor agonists; therefore, we could
not make a pooled estimate. The trial by Bunck et al28 reported that 100% of subjects
achieved FBG <5.6 mmol/l in the insulin glargine arm. Anoth er study/? reported
that 20% of patients achieved FBG <5.6 mmollL in the insulin glarg ine arm.
Postprandial Blood Glucose Levels
Four trials 26-29 reported this indicator in a way that could not contribute to the
meta-analysis. We can only describe the results of these trials, because the conclusions
were consistent. The study by Heine et al26 found that exenaride-rreated patients had
a statistically significant reduct ion, compared with insulin glargine-treated patients,
in after-breakfast (n = 549; MD [95% CI}, -0.91 [-1.39 to -0.43}; P < 0.002) and
after-dinner (n = 549; MD [95 % Cn, -1.41 [-1.89 to -0.93}; P < 0.001) blood glu-
cose. A crossover study-? also reported that the exenatide group was associated with
significantly lower postprandial plasma glucose (PPG) concentrations compared with
the insulin glargine group in the evening (MD [95 % Cl], -1.5 [-2.1 to -0.9}; P <
0.001). The same study found significantly lower 2-hour PPG excursions compared
with insulin glargine in the morning (MD [95 % Cl] , -2.2 [-2 .8 to -1.7}; P < 0.001),
at midday (MD [95 % Cl] , -0.5 [0.9 to -G. I}; P = 0.016), and in the evening (MD
[95% CI}, -2.1 [-2 .7 to -1.5}; P < 0.001). The trial by Bunck et al28 suggested a sig-
nificant reduction of blood glucose after breakfast and after dinner in the exenatide
group, but no specific data were shown. A similar reduction in PPG from baseline was
reported by Russell-Jones et al29 in the liraglutide group (1.81 mmol/l) and insulin
glargine group (1.61 mmol/L).
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CURRENT THERAPEUTIC RESEARCH
PLASMA LIPID LEVELS
Exenatide-treated patients had a statistically significant reduction in LDL-C levels
from baseline to end point (n = 745; MD [95% CI}, -0.18 [-0.28 to -0.08}; P <
0.001) compared with insulin glargine-treated patients, bur there was no significant
difference in regard to TC, HDL-C, or TG (Figure 7).
FASTING AND POSTPRANDIAL INSULIN AND C·PEPTIDE LEVELS
No suitable data could be merged for fasting and postprandial insulin and C-peptide
levels, so we only describe the results of 3 trials. 26,28,29 Heine et al26 suggested that,
after 26 weeks of exenatide treatment, the fasting (P = 0.003) and 2-hour (P = 0.004)
postprandial insulin level and the 1-, 2-, and 3-hour postprandial serum glucose ex-
cursions in patients with T2DM were significantly lower than that in insulin
glargine-treated patients. Bunck er aIlS found that, after 52 weeks of exenatide treat-
ment, there was a statistically significant improvement in first- and second-phase
C-peptide response to glucose with C-peptide response to arginine at 15 mmoliL
glucose concentration (n = 60; P < 0.001). The proinsulin-to-C-peptide ratio was
observed to determine the function of islet p-cells in the study by Russell-Jones
et aL29 They found a significant improvement in the liragluride group compared
with the insulin glargine group (MD [95% CI}, -0.00366 [-0.00597 to -0.00136};
P < 0.002).
WEIGHT (OR BODY MASS INDEX)
The GLP-1 receptor agonists group had significantly greater reduction in weight
from baseline to end point than the insulin glargine group (n = 1473; MD [95% CI},
-3.96 [-5.14 to -2.77}; P < 0.001) (Figure 8). We used the random-effects model to
merge data. The results were consistent through sensitivity analysis for a crossover
design trial (n = 1210; MD [95% CI}, --4.42 [-5.46 to -3.38}; P < 0.001).
BLOOD PRESSURE (SBP/DBP)
Exenatide-treated patients had a significant reduction in SBP (n = 780; MD [95%
CI}, -3.59 [-5.74 to -1.43}; P = 0.001) compared with insulin glargine-treated pa-
tients based on the data of 2 trials (Figure 9).26,30 Because the SD of the BP change
data was unavailable, we only describe the results of the study by Russell-Jones et al.29
They found that liragluride-treated patients had a 4.0-mm Hg decrease, bur insulin
glargine-treated patients had a 0.54-mm Hg increase in SBP (P < 0.001). No signifi-
cant difference in DBP was observed between GLP-1 receptor agonists and insulin
glargine in these trials. 26,29,30
WAIST AND HIP CIRCUMFERENCE, WAIST/HIP RATIO
Two trials 29,30 reported the change of waist circumference, bur no data were avail-
able for a pooled estimate. In the study by Russell-Jones er al,29 the liragluride group
had a 1.50-cm reduction but the insulin glargine group had a 0.89-cm increase (n =
462; MD [95% Cll. -2.39 [-3.14 to -1.65}; P < 0.001). In the study by Davies et al,30
the exenatide group had a 1.90-cm reduction and the insulin glargine group had
224
To
ta
l
St
ud
y
o
r
Su
bg
ro
up
G
LP
-1
R
ec
ep
to
rA
go
ni
st
s
M
ea
n
(S
D)
,
rn
rn
o
t/L
In
su
lin
G
la
rg
in
e
M
ea
n
(S
D)
,
m
m
o
i/L
To
ta
l
M
ea
n
D
iff
er
en
ce
W
ei
gh
t,
%
IV,
Fi
xe
d,
95
%
CI
,r
n
m
o
l/L
M
ea
n
D
iff
er
en
ce
IV,
Fi
xe
d,
95
%
CI
,m
rn
o
l/L
Te D
av
ie
s
e
t
a
l30
-
0.
36
(0
.72
)
10
5
-
0.
21
(0
.73
)
10
8
38
.2
-
0.
15
(-0
.3
4
to
0.
04
)
-
H
ei
ne
e
t
a
l'6
-
0.
08
(0
.84
)
28
2
0.
03
(0
.98
)
26
7
61
.8
-
0.
11
(-0
.2
6
to
0.
04
)
ri
Su
bt
ot
al
(95
%
CI
)
38
7
37
5
10
0
-
0.
13
(-0
.2
5
to
0.
00
)
H
et
er
og
en
ei
ty
:x
'=
0.
10
,d
f=
1
(P
=
0.
75
);
{'
=
0%
Te
st
fo
r
o
ve
ra
ll
e
ffe
ct
:z
=
2.
04
(P
=
0.
04
)
H
D
L-
C
D
av
ie
s
e
t
a
l30
0.
01
(0.
1)
10
1
0.
02
(0.
1)
10
6
50
.6
-
0.
01
(-0
.0
4
to
0.
02
)
~
H
ei
ne
e
t
a
l'6
0.
04
(0
.17
)
28
2
0.
04
(0
.16
)
26
7
49
.4
o
(-0
.0
3
to
0.
03
)
~
Su
bt
ot
al
(95
%
CI
)
38
3
37
3
10
0
-
0.
01
(-0
.0
2
to
0.
01
)
~
H
et
er
og
en
ei
ty
:x
'=
0.
26
,d
f=
1
(P
=
0.
61
);
t'
=
0%
Te
st
fo
r
o
ve
ra
ll
e
ffe
ct
:z
=
0.
51
(P
=
0.
61
)
u
x
-c
D
av
ie
s
e
t
a
i30
-
0.
25
(0
.58
)
95
-
0.
07
(0.
5)
10
1
45
.5
-
0.
18
(-0
.3
3
to
-
0.
03
)
•
H
ei
ne
e
t
a
l'6
-
0.
04
(0
.84
)
28
2
0.
14
(0
.8
2)
26
7
54
.5
-
0.
18
(-0
.3
2
to
-
0.
04
)
•
Su
bt
ot
al
(95
%
CI
)
37
7
36
8
10
0
-
0.
18
(-0
.2
8
to
-
0.
08
)
•
H
et
er
og
en
ei
ty
:X
'=
0.
00
,d
f=
1
(P
=
1.
00
);
/'
=
0%
Te
st
fo
r
o
ve
ra
ll
e
ffe
ct
:z
=
3.
44
(P
<
0.
00
1)
TG Da
vi
es
e
t
a
l30
-
0.
33
(0
.82
)
10
5
-
0.
38
(0
.8
3)
10
8
50
.0
0.
05
(-0
.1
7
to
0.
27
)
•
H
ei
ne
e
t
a
l'6
-
0.
25
(1
.34
)
28
2
-
0.
37
(1
.3
1)
26
7
50
.0
0.
12
(-0
.1
0
to
0.
34
)
-
Su
bt
ot
al
(95
%
CI
)
38
7
37
5
10
0
0.
08
(-0
.0
7
to
0.
24
)
H
et
er
og
en
ei
ty
:x
'=
0.
19
,d
f=
1
(P
=
0.
66
);
t'
=
0%
Te
st
fo
r
o
ve
ra
ll
e
ffe
ct
:z
=
1.
06
(P
=
0.
29
)
Fi
gu
re
7.
Fo
re
st
pl
ot
ill
us
tr
at
in
g
th
e
ch
an
ge
in
fa
st
in
g
pl
as
m
a
lip
id
le
ve
ls
fo
llo
w
in
g
tr
ea
tm
en
tw
ith
gl
uc
ag
on
-li
ke
pe
pt
id
e-
1
(G
LP
-1)
re
c
e
pt
or
ag
on
ls
ts
o
r
in
su
lin
gl
ar
gi
ne
.I
V
=
in
ve
rs
e
v
ar
ia
nc
e;
TC
=
to
ta
lc
ho
le
st
er
ol
;
TG
=
tr
ig
ly
ce
rid
es
.
II) II) 1II
-
0.
2
-
0.
1
0
Fa
vo
rs
G
LP
-1
R
ec
ep
to
rA
go
ni
st
s
0.
1
0.
2
Fa
vo
rs
In
su
lin
G
la
rg
in
e
~ ~ C III -t l> r
n c: :II :II 1'1 Z oj ~ J: 1'1 :II > .. 1'1 c: oj ii :II 1'1 VI 1'1 > :II n J:
4
2
o
-
2M
ea
n
D
iff
er
en
ce
IV
.R
an
do
m
,
95
%
CI
,k
g
~
-
-
-
4
-
-
-
-
-
-
-
-
-
M
ea
n
D
iff
er
en
ce
IV
,R
an
do
m
,9
5%
CI
,k
g
-
3.
96
(-5
.1
4
to
-
2.
77
)
-
3.
40
(-4
.3
1
to
-
2.
49
)
-
3.
40
(-4
.3
1
to
-
2.
49
)
-
2.
20
(-3
.0
3
to
-
1.
37
)
-
-
4.
60
(-6
.5
6
to
-
2.
64
)
-
5.
71
(-6
.5
7
to
-
4.
85
)
-
-
4.
07
(-4
.6
5
to
-
3.
49
)
-
-
4.
11
(-5
.6
2
to
-
2.
60
)
20
.8
20
.8
10
0
21
.3
14
.4
21
.1
22
.5
79
.2
W
ei
gh
t,
%
23
2
23
2
74
0
To
ta
l
12
7 33 10
4
24
4
50
8
In
su
lin
G
la
rg
in
e
1.
6
(5
.03
)
0.
6
(3
.38
)
1.
0
(4.
6)
2.
98
(3
.16
)
1.
75
(3
.28
)
M
ea
n
(S
D)
,k
g
G
LP
-l
R
ec
ep
to
rA
go
ni
st
s
M
ea
n
(S
D)
,k
g
To
ta
l
St
ud
y
o
r
Su
bg
ro
up
Li
ra
gl
ut
ld
e
vs
In
su
lin
G
la
rg
in
e
R
us
se
ll-
Jo
ne
s
e
t
a
l'9
-
1.
8
(5
.0)
23
0
Su
bt
ot
al
(95
%
CI
)
23
0
H
et
er
og
en
ei
ty
:N
ot
a
pp
lic
ab
le
Te
st
fo
r
o
ve
ra
ll
e
ffe
ct
: z
=
7.
29
(P
<
0.
00
1)
To
ta
l(
95
%
CI
)
73
3
H
et
er
og
en
ei
ty
:r
=
1.
54
,x
'=
35
.0
7,
df
=
4
(P
<
0.
00
1)
;/
'=
89
%
Te
st
fo
r
o
ve
ra
ll
e
ffe
ct
:z
=
6.
54
(P
<
0.
00
1)
Ex
en
at
id
e
vs
In
su
lin
G
la
rg
ln
e
Ba
rn
et
te
t
a
l'7
-
1.
6
(3
.5)
13
6
Bu
nc
k
e
t
a
l'8
-
3.
6
(3
.6)
36
D
av
ie
s
e
t
a
l'o
-
2.
73
(3
.1)
10
0
H
ei
ne
e
t
a
l'6
-
2.
32
(3
.1
9)
23
1
Su
bt
ot
al
(95
%
CI
)
50
3
H
et
er
og
en
ei
ty
:"
=
2.
04
,X
'=
33
.6
3,
df
=
3
(P
<
0.
00
1)
;f
2=
91
%
Te
st
fo
r
o
ve
ra
ll
e
ffe
ct
:z
=
5.
35
(P
<
0.
00
1)
III III ClI
Fa
vo
rs
G
LP
-l
R
ec
ep
to
rA
go
ni
st
s
Fa
vo
rs
In
su
lin
G
la
rg
in
e
Fi
gu
re
8.
Fo
re
st
pl
ot
ill
us
tr
at
in
g
th
e
ch
an
ge
in
bo
dy
w
ei
gh
t
fro
m
ba
se
lin
e
to
en
d
po
in
t
fo
llo
w
in
g
tr
ea
tm
en
t
w
ith
gl
uc
ag
on
-li
ke
pe
pt
id
e-
1
(G
LP
-1)
re
ce
pt
or
a
go
nl
st
s
o
r
in
su
lin
gt
ar
gl
ne
,I
V
=
in
ve
rs
e
v
ar
ia
nc
e.
To
ta
l
St
ud
y
o
r
Su
bg
ro
up
G
LP
-l
R
ec
ep
to
r
Ag
on
ist
s
M
ea
n
(S
D)
,
m
m
H
g
In
su
lin
G
la
rg
in
e
M
ea
n
(S
D)
,
m
m
H
g
To
ta
l
M
ea
n
D
iff
er
en
ce
W
ei
gh
t,
%
IV,
Fi
xe
d,
95
%
CI
,m
m
H
g
M
ea
n
D
iff
er
en
ce
IV,
Fi
xe
d,
95
%
CI
,m
m
H
g
To
ta
l (9
5%
CI
)
39
9
H
et
er
og
en
ei
ty
:X
2
=
0.
00
,d
f=
1
(P
=
0.
99
);
J2
=
0%
Te
st
fo
r
o
ve
ra
ll
e
ffe
ct
:z
=
3.
26
(P
=
0.
00
1)
D
av
ie
s
e
t
a
l'o
H
ei
ne
e
t
a1
26
-
2.
9
(1
2.
98
)
11
7
-
4.
15
(1
7.
8)
28
2
0.
7
(1
2.
81
)
-
0.
57
(1
6.
01
)
11
4
26
7
38
1
42
.0
58
.0
10
0
-
3.
60
(-6
.9
3
to
-
0.
27
)
-
3.
58
(-6
.4
1
to
-
0.
75
)
-
3.
59
(-5
.7
4
to
-
1.
43
)
-
2
0
-
-
-
-
-
-
- •
-
1
0
0
10
20
Fa
vo
rs
G
LP
-l
R
ec
ep
to
rA
go
ni
st
s
Fa
vo
rs
In
su
lin
G
la
rg
in
e
N N .....
Fi
gu
re
9.
Fo
re
st
pl
ot
ill
us
tr
at
in
g
th
e
ch
an
ge
in
sy
st
ol
ic
bl
oo
d
pr
es
su
re
fo
llo
w
in
g
tr
ea
tm
en
t
w
ith
gl
uc
ag
on
-li
ke
pe
pt
id
e-
1
(G
LP
-1)
re
ce
pt
or
a
go
nl
st
s
o
r
in
su
lin
gl
ar
gi
ne
.I
V
=
in
ve
rs
e
v
ar
ia
nc
e.
:'i ~ r III -I l> r
CURRENT THERAPEUTIC RESEARCH
a 1.86-cm increase (n = 231; MD [95% CI}, -3.76 [-5.21 to -2.31}; P < 0.001). No
trials reported on indicators of hip circumference or waist/hip ratio.
HYPOGLYCEMIA
The Overall Incidence ofHypoglycemia
No significant difference in the overall incidence of hypoglycemia (%) between
GLP-1 receptor agonists and insulin glargine was observed (n = 796; RR [95% CI},
0.69 [0.42 to 1.14J) (Figure 10). The results of a sensitivity analysis was stable (n =
531; RR [95% CI}, 0.69 [0.27 to 1.74}). The study by Heine et aF6 found no signifi-
cant difference in the overall (end point) incidence of hypoglycemic episodes (events/
patient-year) between exenatide and insulin glargine (n = 549; MD [95% CI}, 1.1
[-1.3 to 3.4J).
Incidence ofNocturnal Hypoglycemic Episodes
Two trials26,27 found that significantly more nocturnal hypoglycemic episodes
(events/patient-year) occurred among insulin glargine-treated patients than exenatide-
treated patients. Heine et aF6 reported 2.4 vs 0.9 episodes, respectively; P < 0.001.
Barnett et aF7 reported 1.3 vs 0.4; P < 0.001. Davies et apo reported a greater inci-
dence of nocturnal hypoglycemia (%) (n = 234; RR [95% CI}, 0.40 [0.23-0.71}; P =
0.002) in insulin glargine-treated patients; however, these trials did not include suit-
able data for a pooled estimate.
ADVERSE EFFECTS
The GLP-1 receptor agonisrs group had significantly more overall incidence of
treatment-emergent AEs (TEAEs) than the insulin glargine group (n = 1510; RR
[95% CI}, 1.23 [1.09-1.39}; P < 0.001) (Figure 11). The result is unchanged after
sensitivity analysis (n = 1245; RR [95% CI}, 1.23 {1.0S-1.44}; P = 0.008).
The details of the specific AEs are shown in Table III. There are significant in-
creases in the incidence of gastrointestinal AEs (eg, nausea, vomiting had P < 0.001;
diarrhea, dyspepsia, constipation, and upper abdominal pain had P :s; 0.01) in the
GLP-1 receptor agonises group compared with the insulin glargine group. No differ-
ence between the 2 groups existed for other AEs such as headache, dizziness, nasophar-
yngitis, cough, back pain, or arthralgia. Only the incidence of influenza had a signifi-
cant increase in the insulin glargine-treated patients (P < 0.05).
COST-EFFECTIVENESS
Four articles32-35reported the cost-effectiveness of exenatide versus insulin glargine
treatment. These patient characteristics and treatment effect data were all derived from
a single RCT.26 Three of the articles were based on data from the United Kingdom,
Germany, and Switzerland. The articles' conclusions are consistent in that exenatide
had higher direct medical costs compared with insulin glargine (the increased cost was
£9912 over a 35-year time horizon, €3854 over a 10-year time horizon, and CHF
[Swiss Franc} 8378 over a 35-year time horizon, respectively, in the 3 settings). But
exenatide treatment suggested comparable or better life expectancyand an improvement
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in quality-adjusted life expectancy (0.442, 0.28, and 0.43 quality-adjusted life-
years [QALYs}, respectively) compared with insulin glargine; the incremental cost-
effectiveness ratio was £22,420, €13,746, and CHF19,450 per QALY gained. The
study by Woehl er aI34 used a different simulation model analysis and found that, for
the higher lifetime medical costs for exenatide and insulin glargine (£14,568 and
£9280 per patient, respectively), exenatide was not cost-effective compared with in-
sulin glargine.
DISCUSSION
There are several (systematic) reviews7,15,36 about GLP-l receptor agonists for T20M,
but few meta-analyses exist that focus on the assessment of GLP-l receptor agonisrs
compared with long-acting insulin analogues. Some recent trials28-3o were not in-
cluded in the previously relevant mera-analysis.t"
The ultimate goal of treating diabetes is to improve mortality, microvascular and
macrovascular complications, and quality oflife. But in this systematic review, we did
not find data regarding mortality and diabetes-related complications. No included
RCTs were specifically designed to evaluate these clinical end point outcomes. Only
1 trial reported health-related quality of life26; a secondary analysis of that study sug-
gested that both exenatide and insulin glargine were associated with significant
improvements in patient-reported outcomes when added to oral medications for patients
with T20MY In general, patient satisfaction is necessary to maximize treatment ef-
fectiveness. Only patients who are satisfied with their treatment will adhere to prescribed
regimens. The secondary analysis also found that treatment satisfaction between the
2 groups was the same.I!
Because evidence on primary end point outcomes was lacking, the efficacy of
GLP-l receptor agonists compared with insulin glargine was assessed on secondary
outcomes (eg, HbA1c' lipids, BP). Many studies have suggested that the incidence of
clinical end point outcomes is significantly associated with glycemic control, lipids,
and Bp'37-42 Meta-analysis of secondary indicators found that GLP-l receptor agonists
compared with insulin glargine were not significantly different in regard to the reduc-
tion of HbA1c levels and more effective at reducing postprandial blood glucose,
LOL-C, SBP, weight, and at improving islet /3-cell function. Patients treated with
insulin glargine had significantly lower FBG levels and a greater percentage of pa-
tients who met targets such as FBG <5.6 mmollL than patients treated with GLP-l
receptor agonists.
In many countries, long-acting insulin analogues are used when diet and oral medi-
cation fail.8 A large number of clinical practices have found that insulin glargine can
reduce basal blood glucose safely and effectively.'' which is consistent with the present
analysis. Obesity is an important risk factor for cardiovascular disease.v' Many pa-
tients with T20M are overweight and obesev'; weighr reduction for these patients to
further reduce the blood glucose and cardiovascular complications is of great signifi-
cance. Moreover, postprandial blood glucose, LOL-C, and SBP are all cardiovascular
disease risk factors. 45,46 If these multiple cardiovascular disease risk factors can be
improved, this may be a good feature for any hypoglycemic agents.
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In addition to evaluating clinical efficacy, TEAEs were also considered in this
meta-analysis. GLP-l receptor agonists were not significantly different compared
with insulin glargine in the overall incidence of hypoglycemia, with a greater overall
incidence of TEAEs, especially gastrointestinal AEs (eg, nausea, vomiting). Insulin
glargine-treated patients had more incidences of nocturnal hypoglycemic episodes
and influenza than GLP-l receptor agonist-treated patients.
GLP-l is associated with satiety and reduced rates of gastric emptying and food
inrake.F These might be a mechanism for the weight loss and gastrointestinal dis-
comfort associated with GLP-l receptor agonists. Some studies 26- 3o found that gas-
trointestinal AEs and weight loss do not always occur in the same patient; moreover,
as GLP-l receptor agonist-treatment continues, such AEs may gradually slow down.
How to create GLP-l receptor agonises that playa role in weight loss, but with fewer
gastrointestinal AEs, is worthy of further study.
The results of this meta-analysis suggest that GLP-l receptor agonists are an option
as the next step of treatment for diabetic patients who have not achieved treatment goals
with oral hypoglycemic agents, especially in overweight or obese patients. However, this
should be further validated by future clinical practice. More trials should focus on the
following aspects: durability of glycemic control, weight loss, improvement of ~-cell
secretory function, prevention of vascular complications, reduction of overall mortality,
decreased medical costs, greater safety, high quality of life, and life expectancy.
LIMITATIONS
There are several potential limitations in this review. First, this meta-analysis was
based on 5 published RCTs. There are many unfinished studies; a relatively small
number of available trials is a porenrial lirnirarion for any meta-analysis. If we obtain
the results of the 11 ongoing trials, this meta-analysis will be updated in the future.
The small number of studies also prevented us from fully assessing the potential for
publication bias. The lack of gray literature (eg, presentations, unpublished data,
government reports, other traditional or nontraditional sources of evidence) is also a
limitation of this systematic review. All included RCTs were sponsored by relevant
pharmaceutical companies (Eli Lilly and Company, Novo Nordisk), and only pub-
lished literature in the English language was retrieved in this meta-analysis, which
may lead to a potential publication bias.
Shorter observation periods and the lack of some important indicators (eg, mortali-
ty and diabetes-related complications) in these included trials are another limitation.
Due to lack of the data regarding long-term follow-up, our meta-analysis still cannot
define the long-term efficacy or safety profiles of GLP-l agonists.
Finally, if the blinding method of the 5 included studies had not been well-
implemented, a higher performance bias might result. These rrials reported that the
reason for using the open-label design in patients receiving long-acting insulin ana-
logue (insulin glargine) treatment was because the patient must use titration methods
to adjust the dose of insulin glargine according to self-monitored blood glucose levels.
It is difficult to carry out blinding for participants (patients) in a clinical trial, but
objective outcomes (eg, blood glucose) would be less influenced by lack of blinding.
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The included trials did not indicate whether statisticians or outcome assessors were
blinded to treatment. Outcome assessors and data analysts might be influenced by
lack of blinding, especially for subjective outcomes (eg, health-related quality of life).
A number of indicators were incomplete or no SD existed in our included trials, which
might affect the results of the meta-analysis.
CONCLUSIONS
In this meta-analysis of 5 RCTs, insulin glargine significantly reduced FBG, but
with a higher rate of nocturnal hypoglycemic episodes and influenza, compared with
GLP-l receptor agonisrs. GLP-l receptor agonists significantly reduced postprandial
blood glucose, LDL-C, SBP, and weight, and improved islet ~-cell function, but had
more associated gastrointestinal AEs compared with insulin glargine. GLP-l receptor
agonists are not significantly different from insulin glargine in regard to the reduc-
tion of HbA1c levels and the overall incidence of hypoglycemia. It remains unclear
whether GLP-l receptor agonists influence mortality or complications in patients
with T2DM.
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